Clinical Trials of Itacitinib for Chronic and Acute GVHD

(2:55)

Itacitinib for the prevention of immune effector cell therapy–associated CRS

(58)

Itacitinib for the prophylaxis of GvHD and CRS in T-cell replete haploidentical PBSCT

(2:20)

Itacitinib and corticosteroids for chronic GvHD

(7:37)

Itacitinib plus alemtuzumab for patients with T-PLL

(2:58)

Itacitinib Clinical Trials for Chronic and Acute GVHD

(3:12)

Effective treatment of low risk acute GVHD with itacitinib monotherapy

(2:29)

The safety and efficacy of itacitinib monotherapy for patients with low-risk GvHD

(1:21)

Itacitinib in patients with acute GvHD

(3:55)

Discussing Rheumatology: Baricitinib and Itacitinib

(7:22)

Phase II trial-in-progress of itacitinib in patients with myelofibrosis

(1:49)

Completed Clinical Trials of JAK Inhibitors for Treatment of Acute GVHD: Itacitinib \u0026 Ruxolitinib

(11:11)

AACR 2021 - Dr. Andrew Kuykendall - ABSTRACT CT236

(2:10)

Everolimus and itacitinib in patients with HL R/R to brentuximab vedotin and checkpoint inhibitors

(2:55)

JAK1 inhibition enhances pembrolizumab efficacy in PD-L1 positive mNSCLC

(54)

How might itacitinib prophylaxis impact haplo-HSCT outcomes in the future?

(7:50)

2022 Clinical Research Forum Top Ten| Development of Pomalidomide in the Treatment of Chronic GVHD

(1:33)

What is the latest update on the GRAVITAS-309 trial?

(3:52)

Ruxolitinib: Treatment of Steroid-Refractory Acute GVHD

(2:42)

CITADEL-101 study- Parsaclisib in R/R B-cell malignancies

(2:28)